Author: Alexander Lee

Amgen has announced the approval of a new oral treatment option for children and adolescents with moderate to severe plaque psoriasis. This marks the first time that young patients and their caregivers have an oral option to address the uncomfortable and visible symptoms of this chronic disease. The efficacy and safety of the treatment, Otezla, were demonstrated in a Phase 3 study called SPROUT, which included pediatric patients aged 6 to 17 years. According to Murdo Gordon, the Executive Vice President of Global Commercial Operations at Amgen, Otezla has been prescribed to over one million adults worldwide in the past…

August 29, 2024 – Aion Therapeutic Inc., a company based in Toronto, Ontario, announced today that the British Columbia Securities Commission (BCSC) has granted a management cease trade order (MCTO) in response to the Company’s application. The MCTO provides the Company with an extension until October 28, 2024, to submit its annual audited consolidated financial statements for the financial year ending April 30, 2024, along with the relevant accompanying documents. Due to the acquisition of Toppen Health, Inc. on December 15, 2023, the Company’s independent auditor requires valuations for Toppen both at the acquisition date and as of April 30,…

In Calgary, Alberta, on August 22, 2024, West High Yield (W.H.Y.) Resources Ltd. (TSXV: WHY) hereby announces the closing of its previously announced private placement offering of units (the “Offering”). The Company issued a total of 435,076 Units, generating gross proceeds of $143,575.05. Each Unit comprised one Common Share of the Company and one half of one Common Share purchase warrant. Each Warrant, along with CAD$0.45, entitles the holder to acquire an additional Common Share for eighteen months from the closing date of each Offering. It should be noted that the Company’s previous news release erroneously stated that each Unit…

On August 29, 2024, Element 29 Resources Inc., a company focused on copper exploration and development, announced the completion of a non-brokered private placement financing. The financing involved the issuance of 13,058,984 units at a price of $0.25 per unit, resulting in total gross proceeds of $3,264,746. Each unit included one common share and one non-transferable common share purchase warrant, exercisable at $0.50 per warrant share until August 29, 2027. Insiders of the company participated in the offering, contributing 2,150,000 units. The company paid aggregate cash finder’s fees of $92,767.50 in connection with the offering. The net proceeds from the…

New Stratus Energy Inc., a corporation based in Calgary, Alberta, is pleased to announce the consolidated financial and operating results for the three and six months ended June 30, 2024. The results have been filed on the SEDAR+ platform. In the second quarter of 2024, the highlights include adjusted working capital of $33,106,553 ($0.23 per common share), a net loss of $161,500 ($0.00 per common share), and income from an investment in a joint venture amounting to $3,621,733. The Corporation’s average production for the second quarter of 2024 was 1,106 boepd, with an exit combined production of 1,281 boepd as…

On August 29, 2024, Torex Gold Resources Inc. reported a tragic incident involving a contract worker at the Guajes Tunnel. The Company expressed deep sorrow over the death of a 40-year-old male contractor who sustained fatal injuries while working in the tunnel. Jody Kuzenko, President & CEO of Torex, conveyed condolences to the family and friends of the deceased and assured full support to them. The Company has halted construction activities at the Media Luna project site and informed the relevant authorities. An investigation will be initiated to determine the cause of the accident and prevent future occurrences. Torex Gold…

Kazatomprom, the leading global uranium producer, announced a revision of its 2025 production targets due to project delays and shortages of sulphuric acid. The company, accounting for a significant portion of the world’s uranium supply, has adjusted its goal for 2025 to a range of 25,000 to 26,500 tons, reflecting a 17% decrease. Regarding the current uranium spot price, it is reported to be at US$78.80 as of the latest update, a slight decline from the previous week’s value of $80.30. In the industry spotlight, Generation Uranium has expanded its presence in the Yathkyed Basin in Nunavut through the acquisition…

On August 29, 2024, Red Light Holland Corp., an Ontario-based company engaged in the production, growth, and sale of functional mushrooms and mushroom grow kits in North America and Europe, as well as a premium brand of psilocybin truffles to the legal recreational market in the Netherlands, released its financial and operational results for the three months ending June 30, 2024. These results include a cash balance of $14.13 million, a 1.6 million revenue increase from the previous year, a gross profit of 40.1%, reduced cash burn, and total assets of $24.0 million. Todd Shapiro, CEO and Director of Red…

Myriad Uranium Corp. has successfully closed another tranche of its non-brokered private placement financing, raising gross proceeds of $1,170,000. The company is pleased to welcome a Swiss uranium fund and other investors to its cap table. The funds raised will be primarily used for the exploration program at the Copper Mountain Uranium Project. Myriad Uranium holds a 75% earnable interest in the Copper Mountain Uranium Project, which has a rich history of exploration and development by Union Pacific in the 1970s. Union Pacific’s drilling efforts resulted in the discovery of multiple uranium deposits and the development of a mine plan…

MindBio Therapeutics recently announced the successful completion of Phase 1 and 2a clinical trials for its depression treatment. The results have shown significant potential, with its treatment for Major Depressive Disorder (MDD), known as MB22001, possibly disrupting the market for depressive illness treatments. Further research has shown that the antidepressant effects of MB22001 are sustained beyond the initial treatment period. This discovery sets a promising stage for the treatment’s efficacy. MindBio stock (CSE:MBIO) last traded at $0.03 per share. The Phase 2a trial of MB22001 focused on patients with MDD and showed positive outcomes. Patients experienced a 60% reduction in…